A compound represented by the following formula (1) (L.sub.1 is a single bond or an unsubstituted arylene group having 6 to 50 ring carbon atoms, and Ar.sub.1 is a substituted or unsubstituted aryl group having 6 to 50 ring carbon atoms).

##STR00001##

A compound represented by the following formula (1) (L.sub.1 is a single bond or an unsubstituted arylene group having 6 to 50 ring carbon atoms, and Ar.sub.1 is a substituted or unsubstituted aryl group having 6 to 50 ring carbon atoms).

##STR00001##

The present invention relates to a 5-membered heteroaryl derivative containing an N, and a pharmaceutical composition for use in preventing or treating mental disorders, containing same as an active ingredient, wherein the derivative is excellent in the triple reuptake inhibitory effect of serotonin, norepinephrine, and dopamine, and thus can be useful in the treatment of mental disorders.

The present invention relates to a 5-membered heteroaryl derivative containing an N, and a pharmaceutical composition for use in preventing or treating mental disorders, containing same as an active ingredient, wherein the derivative is excellent in the triple reuptake inhibitory effect of serotonin, norepinephrine, and dopamine, and thus can be useful in the treatment of mental disorders.

The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same.

A compound represented by Formula:

##STR00001##

, or a pharmaceutically acceptable salt thereof.

A compound, of formula (I):

##STR00001##

suitable for treating a cancer wherein the cancer is susceptible to inhibition of Cbl-B.

A compound, of formula (I):

##STR00001##

suitable for treating a cancer wherein the cancer is susceptible to inhibition of Cbl-B.

The present disclosure relates to a plurality of host materials comprising at least one first host compound represented by the following formula 1 and at least one second host compound represented by the following formula 2, and an organic electroluminescent device comprising the same. By comprising the specific combination of the compound according to the present disclosure as host materials, an organic electroluminescent device having high luminous efficiency and/or long lifespan characteristics can be provided.

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).